Gerhardt Attard, MD, PhD, on Prostate Cancer: Results From an After-Market Study on Enzalutamide
2017 ASCO Annual MeetingGerhardt Attard, MD, PhD, of The Royal Marsden Hospital and The Institute of Cancer Research, discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstract 5004)
Related Videos
Primo Lara, MD, on RCC: Expert Perspective on Three Key Papers
Primo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembro...
John Marshall, MD, and Qian Shi, PhD, on Colon Cancer: Results of the IDEA Trial
John Marshall, MD, of Georgetown University, and Qian Shi, PhD, of the Mayo Clinic, discuss study findings on shortening the duration of adjuvant oxaliplatin-based...
David M. Hyman, MD, on Larotrectinib in TRK Fusion Cancers: Trial Results
David M. Hyman, MD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy of larotrectinib, a selective tropomyosin receptor kinase inhibitor, in adult and ...
Lee S. Schwartzberg, MD: 2017 Update on ICLIO: Adopting Immunotherapy in the Community Setting
Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.
Elizabeth R. Plimack, MD, on Advanced Urothelial Cancer: Expert Perspective
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annu...
